CL2009000257A1 - Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico. - Google Patents

Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico.

Info

Publication number
CL2009000257A1
CL2009000257A1 CL2009000257A CL2009000257A CL2009000257A1 CL 2009000257 A1 CL2009000257 A1 CL 2009000257A1 CL 2009000257 A CL2009000257 A CL 2009000257A CL 2009000257 A CL2009000257 A CL 2009000257A CL 2009000257 A1 CL2009000257 A1 CL 2009000257A1
Authority
CL
Chile
Prior art keywords
treatment
metabolic syndrome
physiologically compatible
compatible salts
substituted imidazolines
Prior art date
Application number
CL2009000257A
Other languages
English (en)
Inventor
Gerhard Jaehne
Antony Bigot
Siegfried Stengelin
Matthias Gossel
Irvin Winkler
Anita Diu-Hercend
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2009000257A1 publication Critical patent/CL2009000257A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Uso de imidazolinas 1,3 sustituidas y de sus sales fisiológicamente compatibles para el tratamiento del síndrome metabólico.
CL2009000257A 2008-02-07 2009-02-05 Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico. CL2009000257A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290132 2008-02-07

Publications (1)

Publication Number Publication Date
CL2009000257A1 true CL2009000257A1 (es) 2009-06-26

Family

ID=39502138

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000257A CL2009000257A1 (es) 2008-02-07 2009-02-05 Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico.

Country Status (5)

Country Link
AR (1) AR071345A1 (es)
CL (1) CL2009000257A1 (es)
TW (1) TW200946114A (es)
UY (1) UY31646A1 (es)
WO (1) WO2009097996A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
EP3570841A4 (en) * 2017-01-18 2020-08-19 Coherus Biosciences, Inc. PPARy AGONIST FOR THE TREATMENT OF HUNTINGTON'S DISEASE
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
CN112759550A (zh) * 2019-11-04 2021-05-07 上海科技大学 一种平滑受体拮抗剂
CN113024513A (zh) * 2021-03-22 2021-06-25 中国药科大学 新型雄激素受体降解剂、制备方法和医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
TW200946114A (en) 2009-11-16
WO2009097996A1 (de) 2009-08-13
UY31646A1 (es) 2009-08-31
AR071345A1 (es) 2010-06-16

Similar Documents

Publication Publication Date Title
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2015002194A1 (es) Inhbidores de erk y sus usos
CL2009000316A1 (es) Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos.
NI201200072A (es) Métodos y composiciones para tratar cáncer
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2008002006A1 (es) Compuestos derivados de morfolin pirimidina, composicion farmaceutica, y su uso como inhibidores de la m-tor-quinasa para el tratamiento de l a inflamacion, cancer, enfermedades inmunes, enfermedad obstructiva pulmonar, enfermedad cardiovascular.
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
ATE530170T1 (de) Paliperidonformulierung mit verzögerter freisetzung
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
CL2008001795A1 (es) Uso de un antagonista par1 en el tratamiento de la fibrilacion atrial.
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina